Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05574712 | A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men… | Phase 2 | withdrawn | Oct 10, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal Investigator has decided not to activate this trial. | Investigator |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to… | Phase 1 | terminated | May 20, 2020 | Mersana Therapeutics | discontinued development program | Other (stated, no rule matched) |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | Phase 1 | terminated | Jan 31, 2022 | Lioe-Fee de Geus-Oei, MD PhD | Reached the stop criteria after the interim analysis | Efficacy / futility |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal… | Phase 2 | terminated | Oct 14, 2016 | Swiss Cancer Institute | Decision Board no further financial support after 3 years of follow-up as remaining patients in… | Funding |
| NCT03533946 | Rucaparib in Nonmetastatic prOstAte With BRCAness(ROAR) | Phase 2 | terminated | May 23, 2018 | University of Utah | New standard of care for study participant population | Other (stated, no rule matched) |
| NCT04102436 | Non-Viral TCR Gene Therapy | Phase 2 | withdrawn | Sep 25, 2019 | National Cancer Institute (NCI) | Difficulty with availability of GLP-grade reagents for manufacturing. | Drug supply |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | Phase 2 | withdrawn | Jan 19, 2023 | University of Arizona | Per Principal Investigator, it is not feasible to move forward with this trial. | Investigator |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed… | Phase 1 | terminated | Jan 22, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | Phase 2 | withdrawn | Sep 5, 2021 | M.D. Anderson Cancer Center | Per PI no participants enrolled | Enrollment / accrual |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic… | Phase 2 | terminated | Mar 5, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate…(HIIT PCa) | N/A | withdrawn | Dec 14, 2021 | The University of Texas Health Science Center at San Antonio | PI left the institution, no subjects were enrolled | Investigator |
| NCT05169372 | Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From…(PET-PSMA) | — | terminated | Dec 23, 2021 | Latin American Cooperative Oncology Group | LACOG and Astellas decided to end the study due to the great difficulty in finding patients with… | Other (stated, no rule matched) |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper… | Phase 1 | terminated | Nov 17, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04727736 | 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer | Phase 2 | terminated | Jan 27, 2021 | Ashok Muthukrishnan | Intervention became FDA-approved | Other (stated, no rule matched) |
| NCT02279693 | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients…(PROSTRACK) | N/A | terminated | Oct 31, 2014 | Centre Georges Francois Leclerc | feasibility problem | Other (stated, no rule matched) |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 5, 2018 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Decision not to continue to the expansion portion of the study | Other (stated, no rule matched) |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | Phase 1 / Phase 2 | terminated | Mar 24, 2021 | THERAPIM PTY LTD | For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM… | Other (stated, no rule matched) |
| NCT02995330 | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic… | Phase 1 | terminated | Dec 16, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | lack of accrual | Enrollment / accrual |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | Phase 3 | terminated | Jul 8, 2020 | Ente Ospedaliero Ospedali Galliera | low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer… | COVID-19 / pandemic |
| NCT03970863 | Focal Therapy for Localized Prostate Cancer | — | withdrawn | Jun 3, 2019 | China Medical University Hospital | difficulty in recruiting participants | Enrollment / accrual |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One…(VERACITY) | Phase 3 | terminated | Apr 14, 2021 | Veru Inc. | Administrative reasons | Other (stated, no rule matched) |
| NCT02478502 | Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer | Phase 2 | terminated | Jun 23, 2015 | University Hospital, Akershus | Insufficient recruitment | Enrollment / accrual |
| NCT04264208 | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate… | Phase 2 | terminated | Feb 11, 2020 | Andrei Iagaru | Lack of accrual due to pandemic and logistics | COVID-19 / pandemic |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Jan 6, 2023 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04304079 | A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted… | N/A | withdrawn | Mar 11, 2020 | Chinese University of Hong Kong | No funding | Funding |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05035732 | A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in… | N/A | withdrawn | Sep 5, 2021 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | N/A | terminated | Jul 30, 2018 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Nov 18, 2021 | Immunic AG | Lack of Efficacy | Efficacy / futility |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04528199 | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer | Phase 1 | terminated | Aug 27, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The Principal Investigator decided to terminate the study because the PI left Hopkins. | Investigator |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical… | Phase 2 / Phase 3 | terminated | Apr 29, 2021 | Qilu Pharmaceutical Co., Ltd. | Phase 2 completed, phase 3 sponsor decided to terminate | Sponsor / business decision |
| NCT00323180 | Investigation of Protein Biomarkers of Prostate Cancer | — | withdrawn | May 9, 2006 | University of New Mexico | PI left institution and no subjects enrolled and this is not a clinical trial. | Investigator |
| NCT00323388 | Identification of Risk Allels for Prostate Cancer | — | withdrawn | May 9, 2006 | University of New Mexico | No subjects enrolled and this is not a clinical trial. Was inadvertently entered in the system. | Enrollment / accrual |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT03858166 | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration… | Phase 4 | terminated | Feb 28, 2019 | Shandong University | Sponsor Termination | Other (stated, no rule matched) |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or… | Phase 3 | terminated | Jun 1, 2020 | Chinese University of Hong Kong | Endpoint reached | Other (stated, no rule matched) |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | Phase 3 | terminated | Jul 21, 2021 | Frederick R. Ueland, M.D. | Slow accrual | Enrollment / accrual |
| NCT04999605 | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Akeso | Too low inclusion rate | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer… | Phase 2 | terminated | Sep 15, 2005 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and…(2-Deoxyglucose) | Phase 1 / Phase 2 | terminated | Mar 11, 2008 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of… | — | withdrawn | Apr 11, 2018 | HKGepitherapeutics | No participants enrolled, leading to insufficient patient numbers to initiate the clinical trial. | Enrollment / accrual |
| NCT04267939 | ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid… | Phase 1 | terminated | Feb 13, 2020 | Bayer | There was no anticipated benefit of the experimental combination as tested over available standard… | Other (stated, no rule matched) |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 18, 2024source: clinicaltrials